Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NBIO new 52 week high. Bid x Ask getting tight!
.59 X .635
THE STOCK MOVES ON AIR!
$NBIO .59 X .635 $1 coming soon.
$NBIO .59 X .635
Whats going on with $DIS crazy swing? Was 3% red now 3% green.
$NBIO .58 printing!!! .63 on the ask. I am telling you guys this is trades on air. No shares are available for sale.
$NBIO from .20 to .58!!!! Just starting... $5.00 by the end of the year.
$NBIO from .20 to .58!!!! Just starting... $5.00 by the end of the year.
$NBIO Clean level 2, no toxic debt, tightly held by management. Low Float Biotech with 2 cancer drugs currently in clinical trials.
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
https://www.nascentbiotech.com/
https://www.otcmarkets.com/stock/NBIO/overview
$NBIO $NBIO $NBIO
$NBIO Clean level 2, no toxic debt, tightly held by management. Low Float Biotech with 2 cancer drugs currently in clinical trials.
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
https://www.nascentbiotech.com/
https://www.otcmarkets.com/stock/NBIO/overview
$NBIO $NBIO $NBIO
$NBIO 2 cancer drugs in clinical trials. Razor thin. The time is now.
$NBIO 2 cancer drugs in clinical trials. Razor thin. The time is now.
I truly believe $NBIO is going to go over $5.00 before years end. I would love some support spreading awareness. Surprised, no one seems to be on this one.
Keep your eyes on $NBIO. This play is just heating up, just needs awreness. No dilution, clean level 2, and 2 cancer drugs in clinical trials. Low float, low monthly burn rate. This is a gem.
$NBIO OTCQB
$NBIO .45 X .515
Biotech Company OTCQB
2 Cancer drugs in trial
Low Float
Clean Level 2
No Dilution
Moves on air. $20,000 in dollar volume puts this well over a dollar.
$NBIO .45 X .515
Biotech Company OTCQB
2 Cancer drugs in trial
Low Float
Clean Level 2
No Dilution
Moves on air. $20,000 in dollar volume puts this well over a dollar.
$NBIO
2 cancer drugs in clinical trials
OTCQB
Clean Level 2
Unusual trading volume
No Dilution
No VERT VFIN or VNDM
www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO spread getting tighter. This thing fly’s. $20,000 in dollar volume puts it well over a dollar.
$NBIO Clean level 2, no toxic debt, tightly held by management. Low Float Biotech with 2 cancer drugs currently in clinical trials.
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
https://www.nascentbiotech.com/
https://www.otcmarkets.com/stock/NBIO/overview
$NBIO $NBIO $NBIO
$NBIO Low Float Biotech with 2 cancer drugs in clinical trials. Unusual volume starting to come in. Stock moves on air.
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
https://www.nascentbiotech.com/
https://www.otcmarkets.com/stock/NBIO/overview
$NBIO Low Float Biotech, 2 drugs currently in clinical trials. Unusual volume for several weeks. The event is near...
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO Low Float Biotech, 2 drugs currently in clinical trials. Unusual volume for several weeks. The event is near...
$NBIO is the play. It is the foundation of why this board was created. Talk about under the radar and a lotto. This is it. Check out the board. Strong DD. Load em boys.
$NBIO fireworks coming soon!
.44
Keep $NBIO on your radar. When the volume comes in, it will fly.
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
Great day here. One day soon I wont be talking to myself. Awareness is coming!!!!
$NBIO is going to be the stock of 2018
$NBIO Investor Presentation
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO 2 cancer drugs undergoing trials. $10,000 pushed this in to dollar land. Nothing available on Level 2. Clean, clean, clean MM's on this one.
https://www.nascentbiotech.com/
$NBIO not much volume will push this over a dollar.
https://www.nascentbiotech.com/
$NBIO about to go .37 X .515
RAZOR RAZOR RAZOR Thin
$NBIO is gearing up for an epic run. Get your tickets now. I will say this it is so thin it is actually difficult to start position. Held so tight.
$NBIO Nascent Biotech is a California-based company focused on the development and delivery of human antibodies and cytokine responses for the treatment of cancer.
The innate ability of the intelligence of the natural human immune system to generate a cancer specific response combined with Nascent Biotech’s technical skills opens the door for immunologically based therapeutics for human cancer.
Nascent Biotech is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.
Our insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.
The company’s technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune boosting and regulation biomolecules.
In our bodies, the natural immune response to harmful agents is both oligoclonal and oligocelluar; that is, several different antibodies and cell types are generated to attach a particular disease agent.
Use of a single monoclonal antibody (mAB), or monotherapy, to treat a disease – the approach employed by most pharmaceutical / biotechnology companies – may not be optimal and is certainly not the preferred natural approach.
Nascent Biotech’s approach to treatment of disease is to “mimic” the body’s natural antibody and cellular reponses by identifying and combining antibodies and natural cytokines into a single therapy for more effective disease treatment.
Nascent Biotech believes that by combining specifically selected biomolecules into a potent “cocktail”, one can create an efficient, multi-targetted attack against disease. Applications of this technology span cancer, metabolic disorders and infectious disease indications.
$NBIO Wide Open, paper thin. Lets get this train started. Solid company, low burn rate, 2 drugs in clinical trials. Its go time.
Easy run to $5 in the months ahead.
SOLID DD, Check out this presentation!!!!
http://www.nascentbiotech.com/wp-content/uploads/2016/12/NBIO-Investor-Presentation-11.12.2016.pdf
$NBIO absolutley moves on air. Razor thin, just getting started. Could hit $5 in the months ahead. Amazing drugs in development.
https://www.otcmarkets.com/stock/NBIO/overview
$NBIO week 2 of its meteoric rise begins now.
$NBIO week 2 of its meteoric rise begins now.
$NBIO $NBIO Screaming from the top of the mountain here fellas, do the research this is a freaking rocket ship fueling up.
$NBIO $NBIO $NBIO
Nascent Biotech Inc. (OTCQB: NBIO)
https://www.nascentbiotech.com/
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Click this link to download a PDF detailing the conference details, and how to register.
Nascent Biotech is a development stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioma and astrocytoma. Pritumumab is a monoclonal antibody that has been tested in Ministry of Health and Welfare approved clinical studies in 249 human brain cancer patients in the nation of Japan. The objective of the Phase I and Phase II human clinical trial was to determine the safety of pritumumab in humans and its efficacy in eliminating tumors or reducing tumor size in patients with brain cancer.
Share Structure
Market Cap
13,785,699
06/07/2018
Authorized Shares
100,000,000
05/31/2018
Outstanding Shares
28,134,079
05/31/2018
Restricted
19,723,969
05/31/2018
Unrestricted
8,410,110
05/31/2018
Held at DTC
3,247,470
05/31/2018
Float
5,056,710
08/07/2017
Par Value
0.00
Recent News
https://finance.yahoo.com/news/nascent-biotech-announces-fast-eligibility-123000444.html
https://finance.yahoo.com/news/nascent-biotech-announces-completion-1-171700110.html
$NBIO, place your bets. Its time for lift off in the weeks ahead. Not much time left to load at these levels.